Drugs /

gnos-pv01

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for gnos-pv01

Gnos-pv01 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating gnos-pv01, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).

MGMT Promoter Methylation Negative is the most frequent biomarker inclusion criterion for gnos-pv01 clinical trials.

Glioblastoma, hepatocellular carcinoma, and malignant glioma are the most common diseases being investigated in gnos-pv01 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Gnos-Pv01
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gnos-pv01 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.